Welcome to our dedicated page for Insulet SEC filings (Ticker: PODD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating pod shipment data, FDA update timelines, or reimbursement risk disclosures inside Insulet鈥檚 multi-hundred-page reports can feel overwhelming. If you have ever searched for 鈥淚nsulet SEC filings explained simply鈥� or wondered how to decode 鈥淚nsulet insider trading Form 4 transactions,鈥� you are not alone. Medical-device accounting, clinical milestones, and supply-chain details are scattered across 10-K, 10-Q, 8-K, and proxy statements, making analysis time-consuming.
Stock Titan solves that problem. Our AI-powered engine parses every new document the moment it hits EDGAR, then delivers concise, plain-English summaries. Need the latest 鈥淚nsulet quarterly earnings report 10-Q filing鈥� without wading through footnotes? Curious about real-time 鈥淚nsulet Form 4 insider transactions鈥� before a material announcement? Want the 鈥淚nsulet annual report 10-K simplified鈥� so you can focus on Omnipod margin trends instead of arcane accounting language? We map each section, flag material events from 8-K filings, and highlight changes in executive stock ownership鈥攁ll in one place.
Here is how professionals use the page:
- Track 鈥淚nsulet executive stock transactions Form 4鈥� within minutes of submission
- Compare pod sales growth by segment using our 鈥淚nsulet earnings report filing analysis鈥�
- Review 鈥淚nsulet proxy statement executive compensation鈥� without sifting through appendices
- See 鈥淚nsulet 8-K material events explained鈥� in context of FDA approvals or supply-chain shifts
- Answer complex questions like 鈥渦nderstanding Insulet SEC documents with AI鈥� in seconds
Whether you monitor insider buying, evaluate clinical trial spending, or model recurring pod revenue, Stock Titan鈥檚 real-time alerts, AI summaries, and complete coverage ensure you never miss a disclosure that matters.
Benjamin Eric, Executive Vice President and Chief Product Experience Officer at Insulet Corporation (PODD), reported the sale of 4,263 shares of Insulet common stock on 08/21/2025 at a price of $332.23 per share. Following the transaction, he beneficially owns 16,736 shares. The Form 4 indicates the sale was made pursuant to an existing Rule 10b5-1 trading plan. The filing also notes that 93 shares were acquired through the company Employee Stock Purchase Plan since his last Form 4. The document is a routine Section 16 disclosure of an insider sale under a pre-established plan and does not disclose additional transactions, derivatives, or other compensatory details.
Michael R. Minogue, a director of Insulet Corporation (PODD), reported multiple transfers of common stock on 08/19/2025 and 08/21/2025. The Form 4 shows transfers described as coming from a GRAT and as bona fide gifts to a trust for the reporting person鈥檚 spouse, who is trustee. The filing lists several paired dispositions and acquisitions of 9,459 and 1,380 shares (transaction code G, gift/transfer). The report discloses post-transaction beneficial ownership amounts including 778 shares held directly and 15,453 shares held indirectly by trust, along with intermediate reported balances (e.g., 11,617, 14,073). The signature is by attorney-in-fact John W. Kapples dated 08/21/2025.
Insulet Corporation (PODD) Form 144 reports a proposed sale of 4,263 shares of common stock through Fidelity Brokerage Services on NASDAQ with an aggregate market value of $1,416,296.49 and an approximate sale date of 08/21/2025. The filing shows the shares to be sold were recently acquired by the seller through restricted stock vesting on 02/14/2025 (2,842 shares), 02/27/2025 (806 shares), and 02/28/2025 (615 shares), with consideration recorded as compensation. No securities were reported sold by the same person in the prior three months. The filer attests they are not aware of any undisclosed material adverse information about the issuer.
Capital Research Global Investors reports beneficial ownership of 4,736,127 shares of Insulet Corporation, equal to 6.7% of the company's outstanding common stock. The filing shows sole voting power for 4,730,490 shares and sole dispositive power for 4,736,127 shares, with no shared voting or dispositive authority reported.
The statement classifies the filer as an investment adviser and includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. This is a routine institutional ownership disclosure reflecting a material passive stake above the 5% threshold.
Insulet Corporation insider report: Prem Singh, SVP, Global Operations, reported multiple equity transactions dated 08/07/2025 involving common stock and stock options of Insulet (PODD). The Form 4 shows two acquisitions of common stock for 585 shares at $264.69 and 758 shares at $276.36, and a disposition of 1,343 shares sold at $320. The filing states these transactions were effected under an existing Rule 10b5-1 trading plan. The report also discloses annual non-qualified stock option awards: 585 options at a $264.69 exercise price (expiring 02/28/2032) and 758 options at a $276.36 exercise price (expiring 02/28/2033), each vesting in substantially equal installments over four years. The document lists line-by-line beneficial ownership figures corresponding to each transaction.
FAQ
What is the current stock price of Insulet (PODD)?
What is the market cap of Insulet (PODD)?
